Partner Mike Overly was quoted in a Modern Healthcare article, “Wider HIPAA Audits May Drive Stronger Vendor Contracts,” on March 23, 2016. The article discussed the announcement that vendors of healthcare organizations, termed “business associates,” will be included as primary targets in the second round of HIPAA audits by the U.S. Department of Health and Human Services’ Office for Civil Rights (OCR). The audits are intended to clamp down on vendors handling patient data for healthcare organizations to ensure HIPAA-compliance and minimize security failures that could lead to a data breach. The announcement also suggests that enforcement of the OCR’s more stringent privacy and security rules could give healthcare organizations more leverage to get stronger agreements with their vendors.
Overly was quoted saying, “It will force greater visibility into what’s going on – and greater accountability. In many instances, covered entities don’t have the right to go in and audit what a business associate is doing.” He continued to explain, now that business associates are legally liable to the feds for compliance with HIPAA privacy and security rules, “covered entities will insist on having some kind of audit rights” when they sign HIPAA-mandated agreements with these vendors.
Overly was quoted saying, “It will force greater visibility into what’s going on – and greater accountability. In many instances, covered entities don’t have the right to go in and audit what a business associate is doing.” He continued to explain, now that business associates are legally liable to the feds for compliance with HIPAA privacy and security rules, “covered entities will insist on having some kind of audit rights” when they sign HIPAA-mandated agreements with these vendors.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”